Search





Search





Markets
/
Stocks
/
rlay
/

Relay Therapeutics Inc

RLAY

Add to Watchlist

18.830USD

-0.620-3.19%

Close 07-31 16:00（ET）Quotes delayed by 15 min

4.06BMarket Cap

LossP/E TTM

Relay Therapeutics Inc

18.830

-0.620-3.19%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

-3.19%

5 Days

+2.11%

1 Month

+6.02%

6 Months

+145.82%

Year to Date

+122.58%

1 Year

+460.42%

Key Figures

19.760Open

19.760High

1.79MVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

1.03%Turnover Ratio

19.450Prev. Close

18.450Low

25.06MTurnover

LossP/E Static

5.77P/B

0.00%Div Yield TTM

-36.39%ROA

17.32052wk High

0.70Volume Ratio

-337.71MNet Profit

173.87MShares

-1.5634EPS TTM

1.76Beta

-40.01%ROE

2.91052wk Low

6.74%Amplitude

100.00%Gross Margin

4.06BMarket Cap

0.67Reward/Risk

4.33%Risk Rate

TradingKey Stock Score of Relay Therapeutics Inc

Currency: USD Updated: 2026-07-31

Key Insights

Relay Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 42 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.92.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Relay Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

42 / 385

Overall Ranking

113 / 4281

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Relay Therapeutics Inc Highlights

StrengthsRisks

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

Growing

The company is in a growing phase, with the latest annual income totaling USD 15.36M.

Undervalued

The company’s latest PE is -12.04, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 194.30M shares, decreasing 1.84% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 507.28K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.15.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

25.917

Target Price

+41.08%

Upside Space

Relay Therapeutics Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 14 analysts

Buy

Current Rating

25.917

Target Price

+41.08%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

496

Total

Median

Average

Company name

Ratings

Analysts

Relay Therapeutics Inc

RLAY

Beigene Ltd

ONC

argenx SE

ARGX

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

Insmed Inc

INSM

...

Indicators

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.446

Neutral

RSI(14)

53.000

Neutral

STOCH(KDJ)(9,3,3)

47.070

Buy

ATR(14)

1.088

High Vlolatility

CCI(14)

-10.627

Neutral

Williams %R

58.209

Sell

TRIX(12,20)

0.337

Sell

StochRSI(14)

38.962

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

18.716

Buy

MA10

18.886

Sell

MA20

19.224

Sell

MA50

17.006

Buy

MA100

14.815

Buy

MA200

11.351

Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Relay Therapeutics Inc Info

Ticker SymbolRLAY

CompanyRelay Therapeutics Inc

CEOPatel (Sanjiv K)

Websitehttps://relaytx.com/

Shareholders

Shareholders

Proportion

SB Investment Advisers (UK) Limited

14.57%

Commodore Capital LP

8.87%

Point72 Asset Management, L.P.

7.23%

Casdin Capital, LLC

6.79%

BlackRock Institutional Trust Company, N.A.

5.49%

Other

57.05%

Popular Instruments

FAQs

What is the current price of Relay Therapeutics Inc (RLAY)?



The current price of Relay Therapeutics Inc (RLAY) is 18.83.

What is the symbol of Relay Therapeutics Inc?



The ticker symbol of Relay Therapeutics Inc is RLAY.

What is the 52-week high of Relay Therapeutics Inc?



The 52-week high of Relay Therapeutics Inc is 17.32.

What is the 52-week low of Relay Therapeutics Inc?



The 52-week low of Relay Therapeutics Inc is 2.91.

What is the market capitalization of Relay Therapeutics Inc?



The market capitalization of Relay Therapeutics Inc is 3.27B.

Is Relay Therapeutics Inc (RLAY) currently rated as Buy, Hold, or Sell?



According to analysts, Relay Therapeutics Inc (RLAY) has an overall rating of Buy, with a price target of 25.92.

What is the Earnings Per Share (EPS TTM) of Relay Therapeutics Inc (RLAY)?



The Earnings Per Share (EPS TTM) of Relay Therapeutics Inc (RLAY) is -1.61.